Suggested remit: To appraise the clinical and cost effectiveness of sodium thiosulfate within its marketing authorisation for preventing ototoxicity in people aged 1 month to 17 years old with localised cancer having cisplatin chemotherapy.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 1001

Provisional Schedule

Committee meeting: 1 11 September 2024

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Fennec Pharmaceuticals
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups National Deaf Children’s Society
  Royal National Institute for Deaf People
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Neonatal and Paediatric Pharmacists Group
  Royal College of Physicians
Associated public health groups None
Evidence review group School of Health and Related Research (ScHARR)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
13 February 2024 Invitation to participate
07 February 2024 Topic selection
07 February 2024 The topic was considered by the Topic Selection Oversight Panel (TSOP) in January 2024. The panel concluded that a routing to the Technology Appraisal (TA) programme is appropriate for this topic.
28 November 2023 - 05 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1001
28 November 2023 In progress. Scoping commenced.
27 October 2023 Please note that following on from a request received from the company, the timelines for this evaluation have been revised and the evaluation is now anticipated to begin during mid-February 2024 when we will write to you about how you can get involved.
22 January 2021 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of sodium thiosulfate within its marketing authorisation for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy. Please note that following advice received from the company the timelines for this appraisal are to be confirmed. We hope to have a further update for you in due course.
22 January 2021 In progress. Topic is in progress
11 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
23 January 2020 - 20 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual